Engineered acid alpha-glucosidase variants
US11970722B2 · kind B2 · utility
3Cited by
131References
39Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2020 |
| Grant date | Apr 30, 2024 |
| Priority date | — |
| Expiry date | Apr 8, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02E50/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.